(NewsDirect)
Race Oncology Ltd(ASX:RAC) executive director Dr Pete Smith discusses with Proactiveimpressive Phase 2 clinical trial results from its Acute MyeloidLeukaemia (AML) clinical trial. The interim clinical results are froman ongoing investigator-initiated Phase 2 trial of bisantrene incombination with fludarabine and clofarabine in relapsed or refractoryacute myeloid leukaemia patients. Administered over four days, thedrug combination induced a clinical response in 40% of evaluablepatients with five patients receiving a potentially curative stem celltransplant.
“Tosee such meaningful clinical responses in a group that would typicallybe receiving palliative care is striking," said Smith.
"It is alsoencouraging that the safety profile was manageable, even for thisadvanced patient population.
"These are highly positive outcomes in aheavily pretreated patient population.”
ContactDetails
Proactive Investors
GreggCastano
+1 203-762-5649
Copyright (c) 2023 TheNewswire - All rights reserved.